A PYMNTS Company

Federal Trade Commission Rejected in “Reverse Payment” Suit

BY | June 27, 2012

Kevin Noonan, Jun 27, 2012 The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding generic drugs. This threat is…

Kevin Noonan, Jun 27, 2012

The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding generic drugs. This threat is posed by the practice of “reverse payments” in ANDA litigation. Typically, in these arrangements a branded drug manufacturer settles litigation with a generic challenger brought under the Hatch-Waxman Act and such settlements often involve a payment from the branded to the generic drug maker.

In the FTCR

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.211.117.197

Please verify email or join us to access premium content!